Capital Square
PFE icon

Capital Square’s Pfizer PFE Stock Holding History

Capital Square’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$359K Sell
12,572
-471
-4% -$12.5K 0.16% 140
2026
Q2 		$315K Sell
13,043
-275
-2% -$7.19K 0.14% 161
2026
Q1 		$360K Buy
13,318
+12
+0.1% +$319 0.17% 140
2025
Q4 		$331K Sell
13,306
-1,337
-9% -$33.7K 0.17% 134
2025
Q3 		$373K Buy
14,643
+332
+2% +$8.19K 0.19% 117
2025
Q2 		$367K Buy
14,311
+1,693
+13% +$39.5K 0.2% 122
2025
Q1 		$320K Buy
12,618
+20
+0.2% +$523 0.19% 123
2024
Q4 		$329K Sell
12,598
-170
-1% -$4.61K 0.19% 127
2024
Q3 		$370K Buy
12,768
+354
+3% +$10.3K 0.22% 113
2024
Q2 		$367K Buy
12,414
+473
+4% +$13K 0.24% 104
2024
Q1 		$331K Buy
11,941
+209
+2% +$5.8K 0.23% 103
2023
Q4 		$338K Sell
11,732
-4,200
-26% -$127K 0.38% 70
2023
Q3 		$500K Sell
15,932
-1,250
-7% -$44.2K 0.67% 45
2023
Q2 		$630K Buy
17,182
+533
+3% +$20.7K 0.58% 56
2023
Q1 		$691K Buy
16,649
+694
+4% +$30K 0.64% 52
2022
Q4 		$818K Sell
15,955
-4,648
-23% -$223K 0.74% 46
2022
Q3 		$901K Sell
20,603
-1,934
-9% -$94K 0.82% 38
2022
Q2 		$1.18M Sell
22,537
-6,406
-22% -$326K 0.98% 34
2022
Q1 		$1.5M Sell
28,943
-2,501
-8% -$130K 1.07% 24
2021
Q4 		$1.75M Sell
31,444
-1,802
-5% -$89.3K 1.21% 20
2021
Q3 		$1.43M Sell
33,246
-1,446
-4% -$64.1K 1.01% 30
2021
Q2 		$1.42M Buy
34,692
+7,821
+29% +$304K 1.05% 29
2021
Q1 		$983K Sell
26,871
-431
-2% -$15.3K 0.73% 43
2020
Q4 		$1M Buy
27,302
+618
+2% +$22.7K 0.84% 38
2020
Q3 		$929K Buy
26,684
+2,212
+9% +$77.6K 0.96% 31
2020
Q2 		$759K Buy
24,472
+1,125
+5% +$38.2K 0.81% 37
2020
Q1 		$723K Buy
23,347
+3,476
+17% +$118K 0.84% 29
2019
Q4 		$738K Buy
+19,871
New +$708K 0.7% 41

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
D.A. Davidson & Co
D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

Capital Square's PFE Position: Q3 2026 in Review

Capital Square reduced its Pfizer (PFE) stake by 3.6% in Q3 2026, selling an estimated $12.5K and leaving 12,572 shares worth $359K. The position accounts for 0.16% of the portfolio, ranked #140.

Capital Square first reported a position in PFE in Q4 2019 and has held it in 28 quarters since. The position peaked at $1.75M in Q4 2021. 1,101 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Capital Square held 12,572 shares of Pfizer worth $359K as of Q3 2026.
  • Capital Square sold 471 Pfizer shares in Q3 2026, an estimated $12.5K.
  • Pfizer made up 0.16% of Capital Square's portfolio in Q3 2026, its #140 holding.
  • Capital Square first reported a position in Pfizer in Q4 2019 and has held it in 28 quarters since.
  • Capital Square's Pfizer position peaked at $1.75M in Q4 2021.
  • 1,101 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Capital Square's 13F filing for Q3 2026, filed 19 Oct 2026.